Avon Longitudinal Study of Parents and Children (ALSPAC), a cohort study of children born in England during 1991 and 1992.
The Cancer Genome Project at the Wellcome Trust Sanger Institute.
The Diamond Light Source, the UK's national synchrotron science facility in Oxfordshire.
Read the full text
Developing Excellence in Leadership, Training and Science Initiative (DELTAS), a collaboration with the Department for International Development (DFID) to establish cutting-edge research and training programmes across the African continent.
The Ebola Emergency Initiative, a fast-tracked research programme with the goal of identifying clinical and public health interventions to counter the West African Ebola Epidemic.
The Juvenile Diabetes Research Foundation/ Wellcome Trust Diabetes and Inflammation Laboratory facilitates research into the genetic component of type 1 diabetes and is based in the Cambridge Institute for Medical Research.
The Seeding Drug Discovery Initiative.
The Structural Genomics Consortium, an international organisation focussing on three-dimensional structures of proteins of medical relevance with an emphasis on open data.
The Wellcome Trust Sanger Institute, a non-profit, British genomics and genetics research institute.
UK Biobank.
Asia and Africa Programmes
The KEMRI-Wellcome Trust Research Programme, established in 1989 in partnership with the Kenya Medical Research Institute.
The Malawi-Liverpool-Wellcome Trust Clinical Research Programme, was established in 1995.
The Africa Centre for Health and Population Studies in South Africa now known as AHRI African Health Research Institute, established in 1998 in partnership with the South African Medical Research Council.
The Wellcome Trust-Mahidol University-Oxford Tropical Medicine Research Programme in partnership with the Faculty of Tropical Medicine, Mahidol University, researching in Thailand and Laos and was established in 1979.
The Vietnam Research Programme and Oxford University Clinical Research Unit in Ho Chi Minh City and Hanoi.
Seeding Drug Discovery Initiative
Also known as SDDI, this five-year initiative started in October 2005 with the remit "to facilitate the development of drug-like small molecules that address unmet medical needs." SDDI was based in London and managed by Richard Davis. Through early 2010, SDDI had provided more than £80 million across 30 projects split between academic institutions and companies. To early 2010, all but one of the company recipients were either start-ups or spin-outs. In May 2010, an additional £110 million was added to the SDDI fund with the intent to extend the initiative for an additional five years.
Supporting global research and development in COVID-19
The Wellcome Trust announced the need for at least $8 billion of new funding for research, development, and supply of treatments related to COVID-19. Wellcome Trust collaborated with the Bill & Melinda Gates Foundation and Mastercard to fund the COVID-19 Therapeutics Accelerator, launching in March 2020 with an initial $125 million in backing.
Improving research culture
In September 2019, Wellcome launched an initiative to reimagine research and improve the culture in which research is conducted. Current incentive structures and, as a result, culture and practices, prioritise publication outputs above all else. This is damaging people's wellbeing and undermining the quality of research itself.
Membership in the Global Health Innovative Technology Fund (GHIT)
In the summer of 2015, the Wellcome Trust joined the Japanese government, 7 Japanese pharmaceutical and diagnostics companies, The Bill and Melinda Gates Foundation, and the United Nations Development Program as funding partner of the Global Health Innovative Technology Fund (GHIT), which funds scientific research and development for anti-infectives and diagnostics for diseases that primarily affect the developing world.
